Mast cells – a new view of the old acquaintances
Authors:
H. Maxová; M. Vízek
Published in:
Čas. Lék. čes. 2010; 149: 319-323
Category:
Review Article
Overview
Mast cells are well known as the producers of histamine and major effectors of type1 hypersensitivity. They play however an important role in many other physiological and pathological processes. Lesser-known is their role in the processes such as a termination of pregnancy and initiation of delivery. The mast cells are considered as the modulators of endocrine signals on the local reactions in uterus. Many substances produced by the mast cells have the angiogenic effects known primarily for their role in tumour growth, but they influence also embryonal and postnatal growth or process of wound healing. Mast cells also participate in a number of compensatory reactions in the tissue response to the mechanical load, hypoxia or inflammation (airway remodelling in asthma, remodelling of pulmonary vessels in chronic hypoxia, myocardial hypertrophy, liver cirrhosis, chronic pancreatitis). This review describes recent concepts of their role in labour, non-cancerous angiogenesis and remodelling of pulmonary vasculature during chronic hypoxia.
Key words:
mast cells, mediators, labour, angiogenesis, remodelling, pulmonary vessels, hypoxia.
Sources
1. Ehrlich P. Beiträge zur Theorie und Praxis der histologischen Färbung. Thesis, Liepzig University 1878.
2. Hakim-Rad K, et al. Mast cells: makers and breakers of allergic inflammation. Curr Opin Allergy Clin Immunol 2009; 9: 427–430.
3. Metcalfe DD. Mast cells and mastocytosis. Blood 2008; 112: 946–956.
4. Schulman ES, et al. Heterogeneity of human mast cells. J Immunol 1983; 131: 1936–1941.
5. Tabares L, et al. Relationship between fusion pore opening and release during mast cell exocytosis studied with patch amperometry. Biochem Soc Trans 2003; 31: 837–841.
6. Irani AA, et al. Two types of human mast cells that have distinct neutral protease compositions. Proc Natl Acad Sci USA 1986; 83: 4464–4468.
7. Krishnaswamy G, et al. The human mast cell: an overview. Methods Mol Biol 2006; 315: 13–34.
8. Janicki JS, et al. Cardiac mast cell regulation of matrix metalloproteinase-related ventricular remodeling in chronic pressure or volume overload. Cardiovasc Res 2006; 69: 657–665.
9. Welle M. Development, significance, and heterogeneity of mast cells with particular regard to the mast cell-specific proteases chymase and tryptase. J Leukoc Biol 1997; 61: 233–245.
10. Stenton GR, et al. Role of intestinal mast cells in modulating gastrointestinal pathophysiology. Ann Allergy Asthma Immunol 1998; 81: 1–11.
11. Galli SJ, Tsai M. Mast cells: versatile regulators of inflammation, tissue remodeling, host defense and homeostasis. J Dermatol Sci 2008; 49: 7–19.
12. Gordon JR, Galli SJ. Release of both preformed and newly synthesized tumor necrosis factor-α (TNF-α)/cachectin by mouse mast cells stimulated via the FcεRI. A mechanism for the sustained action of mast cell-derived TNF-α. during IgE-dependent biological responses. J Exp Med 1991; 174: 103–107.
13. Taildeman J, et al. Human mast cells express leptin and leptin receptors. Histochem Cell Biol 2009; 131: 703–711.
14. Rudolph MI, et al. Uterine mast cells: a new hypothesis to understand how we are born. Biocell 2004; 28: 1–11.
15. Bosquiazzo VL, et al. Mast cell degranulation in rat uterine cervix during pregnancy correlates with expression of vascular endothelial growth factor mRNA and angiogenesis. Reproduction 2007; 133: 1045–1055.
16. Varayoud J, et al. Mast cells degranulation affects angiogenesis in the rat uterine cervix during pregnancy. Reproduction 2004; 127: 379–387.
17. Bytautiene E, et al. The effect of a mast cell degranulating agent on vascular resistance in the human placental vascular bed and on the tone of isolated placental vessels. Reprod Sci 2008; 15: 26–32.
18. Yokoi H, et al. High incidence of uterine inversion in mast cell-deficient osteopetrotic mutant mice of mi/mi genotype. Biol Reprod 1994; 50: 1034–1039.
19. Schmidt A, et al. Lovastatin-stimulated superinduction of E-selectin, ICAM-1 and VCAM-1 in TNF-alpha activated human vascular endothelial cells. Atherosclerosis 2002; 164: 57–64.
20. Osman I, et al. Leukocyte density and pro-inflammatory cytokine expression in human fetal membranes, decidua, cervix and myometrium before and during labour at term. Mol Hum Reprod 2003; 9: 41–45.
21. Huang J, et al. Cellular localization and hormonal regulation of inducible nitric oxide synthase in cycling mouse uterus. J Leukoc Biol 1995; 57: 27–35.
22. Swindle EJ, Metcalfe DD. The role of reactive oxygen species and nitric oxide in mast cell-dependent inflammatory processes. Immunol Rev 2007; 217: 186–205.
23. Konopka TE, et al. Nitric oxide synthase II gene disruption: implications for tumor growth and vascular endothelial growth factor production. Cancer Res 2001; 61: 3182–3187.
24. Milne SA, et al. Co-localization of matrix metalloproteinase-1 and mast cell tryptase in the human uterus. Mol Hum Reprod 2001; 7: 559–565.
25. Vasiadi M, et al. Progesterone inhibits mast cell secretion. Int J Immunopathol Pharmacol 2006; 19: 787–794.
26. Hattori Y, et al. Vascular expression of matrix metalloproteinase-13 (collagenase-3) in basal cell carcinoma. Exp Mol Pathol 2003; 74: 230–237.
27. Vega E, Rudolph MI. Characterization of oxytocin receptors and serotonin transporters in mast cells. Endocrine 2002; 18: 167–172.
28. Kempuraj D, et al. Corticotropin-releasing hormone and its structurally related urocortin are synthesized and secreted by human mast cells. Endocrinology 2004; 145: 43–48.
29. Norrby K. Mast cells and angiogenesis. Apmis 2002; 110: 355–371.
30. Maltby S, et al. Mast cells in tumor growth: angiogenesis, tissue remodelling and immune-modulation. Biochim Biophys Acta 2009; 1796: 19–26.
31. Norrby K, et al. Mast-cell-mediated angiogenesis: a novel experimental model using the rat mesentery. Virchows Arch B Cell Pathol Incl Mol Pathol 1986; 52: 195–206.
32. Davis GE, Senger DR. Endothelial extracellular matrix: biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization. Circ Res 2005; 97: 1093–1107.
33. Tchougounova E, et al. A key role for mast cell chymase in the activation of pro-matrix metalloprotease-9 and pro-matrix metalloprotease-2. J Biol Chem 2005; 280: 9291–9296.
34. Novotná J. Pojivové bílkoviny periferních plicních cév při chronické hypoxii. Čs Fyziol 2009; 2: 49–52.
35. Novotná J, Herget J. Possible role of matrix metalloproteinases in reconstruction of peripheral pulmonary arteries induced by hypoxia. Physiol Res 2002; 51: 323–334.
36. Herget J, et al. A possible role of oxidant tissue injury in the development of pulmonary hypertension. Physiol Res 2000; 49: 493–501.
37. Novotná J, et al. Hyperoxia and recovery from hypoxia alter collagen in peripheral pulmonary arteries similarly. Physiol Res 2001; 50: 153–163.
38. Vajner L, et al. Acute and chronic hypoxia as well as 7-day recovery from chronic hypoxia affects the distribution of pulmonary mast cells and their MMP-13 expression in rats. Int J Exp Pathol 2006; 87: 383–391.
39. Maxova H, et al. In vitro hypoxia increases production of matrix metalloproteinases and tryptase in isolated rat lung mast cells. Physiol Res 2008; 57: 903–910.
40. Maxová H, et al. Effect of N-acetylcysteine on tissue metalloproteinases activity in RBL-2H3 mast cells exposed to 24 hours of “in vitro” hypoxia. Phys Res 2004; 53: 24P.
41. Lachmanova V, et al. N-acetylcysteine inhibits hypoxic pulmonary hypertension most effectively in the initial phase of chronic hypoxia. Life Sci 2005; 77: 175–182.
42. Banasova A, et al. Prevention of mast cell degranulation by disodium cromoglycate attenuates the development of hypoxic pulmonary hypertension in rats exposed to chronic hypoxia. Respiration 2008; 76: 102–107.
43. Riley DJ, et al. Role of proteolysis and apoptosis in regression of pulmonary vascular remodeling. Physiol Res 2000; 49: 577–585.
44. Maxová H, et al. Prevention of mast cell degranulation by disodium cromoglycate delayed the regression of hypoxic pulmonary hypertension in rats. Respiration (Published online: April 10, 2010).
45. Hara M, et al. Evidence for a role of mast cells in the evolution to congestive heart failure. J Exp Med 2002; 195: 375–381.
46. Esposito I, et al. Mast cell distribution and activation in chronic pancreatitis. Hum Pathol 2001; 32: 1174–1183.
47. Joseph J, et al. Protective role of mast cells in homocysteine-induced cardiac remodeling. Am J Physiol Heart Circ Physiol 2005; 288: H2541–2545.
48. Miyazawa S, et al. Role of mast cells in the development of renal fibrosis: use of mast cell-deficient rats. Kidney Int 2004; 65: 2228–2237.
49. Maxová H, et al. Kromoglykát sodný – blokátor degranulace žírných buněk v procesu tkáňové remodelace. Čs Fyziol 2010; 59: 21–23.
50. Gopalan R, Goldberg S. Tranilast in the Therapy of Coronary Artery Disease. Curr Interv Cardiol Rep 2000; 2: 149–156.
51. Shiota N, et al. Tranilast suppresses vascular chymase expression and neointima formation in balloon-injured dog carotid artery. Circulation 1999; 99: 1084–1090.
Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain managementArticle was published in
Journal of Czech Physicians
Most read in this issue
- Gallstone ileus – the diagnostic and therapeutic challenge
- Mast cells – a new view of the old acquaintances
- Alterations in fatty acid composition of plasma and erythrocyte lipids in critically Ill patients during sepsis
- The prevalence of metabolic syndrome in women with polycystic ovary syndrome